| Literature DB >> 32440168 |
Xiao Chen1,2, Qiaoyun Zhu2, Yanchao Liu2, Ruonan Wang2, Hongyi Xie3, Jiayao Chen4, Ying Cheng5, Haiping Zhang6, Lijun Cao7, Yu Chen1,2.
Abstract
OBJECTIVE: Vibrio parahaemolyticus is a major diarrhoea-inducing pathogen in coastal areas. In this study, we analysed the pathogenic characteristics of and variation in V. parahaemolyticus isolated from acute diarrhoeal patients in seven hospitals in different areas of southeastern China from 2013 to 2017.Entities:
Keywords: Acute diarrhoea; Vibrio parahaemolyticus; antimicrobial resistance; serotypes; virulence genes
Year: 2020 PMID: 32440168 PMCID: PMC7211313 DOI: 10.2147/IDR.S234186
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Detection and Distribution of Vibrio parahaemolyticus in Patients with Acute Diarrhoea in Southeastern China from 2013 to 2017
| Year | Samples | Positive | Rate % |
|---|---|---|---|
| 2013 | 3348 | 204 | 6.1 |
| 2014 | 2892 | 205 | 7.1 |
| 2015 | 1874 | 142 | 7.6 |
| 2016 | 3735 | 266 | 7.1 |
| 2017 | 4655 | 403 | 8.7 |
Demographic Characteristics of the Patients with Acute Diarrhoea from Which Vibrio parahaemolyticus Was Isolated in Southeastern China from 2013 to 2017
| Variable and Category | Total Cases | Vibrio Parahaemolyticus | P | |
|---|---|---|---|---|
| Cases (%) | Isolation Rate (%) | |||
| Gender | 0.982* | |||
| Male | 7889 | 596(48.9) | 7.6 | |
| Female | 7836 | 592(48.5) | 7.6 | |
| Unknown | 789 | 32(2.6) | 4.1 | |
| Age | <0.001* | |||
| ≤4 | 3953 | 12(1.0) | 0.3 | |
| 5–17 | 938 | 64(5.2) | 6.8 | |
| 18–44 | 6758 | 849(69.6) | 12.6 | |
| 45–59 | 1919 | 176(14.4) | 9.2 | |
| ≥60 | 2147 | 87(7.1) | 4.1 | |
| Unknown | 789 | 32(2.6) | 4.1 | |
| Time | <0.001 | |||
| March-May | 2308 | 40(3.3) | 1.7 | |
| June-August | 10,182 | 917(75.2) | 9.0 | |
| September-November | 3450 | 262(21.5) | 7.6 | |
| December-February | 564 | 1(0.1) | 0.2 | |
Notes: *The P value does not include cases of unknown sex and age.
Distribution of Serotypes of Vibro parahaemolyticus Isolates from Patients with Acute Diarrhoea in Southeastern China from 2013 to 2017
| O Serotypes | Serotype (No. of Isolates) | ||||
|---|---|---|---|---|---|
| 2013 (n=204) | 2014 (n=205) | 2015 (n=142) | 2016 (n=266) | 2017 (n=403) | |
| O1(42) | O1:K36(4) | O1:K36(1) | O1:K17(1) | O1:K25(2) | O1:K1(1) |
| O2(9) | O2:K3(2) | – | O2:K3(1) | O2:K3(2) | O2:K28(3) |
| O3(598) | O3:K21(1) | O3:K29(4) | O3:K6(91) | O3:K54(1) | O3:K1(2) |
| O4(491) | O4:K13(5) | O4:K13(1) | O4:K25(1) | O4:K55(1) | O4:K10(1) |
| O5(14) | O5:K17(1) | O5:K52(1) | O5:K6(1) | O5:KUT(2) | O5:K17(1) |
| O6(3) | – | O6:KUT(1) | O6:K18(1) | O6:K18(1) | – |
| O8(6) | O8:K41(2) | O8:K41(1) | – | – | O8:K41(1) |
| O10(32) | O10:K60(5) | O10:K60(5) | O10:K60(2) | O10:K60(7) | O10:K60(6) |
| O11(7) | O11:KUT(2) | O11:KUT(2) | O11:KUT(2) | O11:KUT(1) | – |
| OUT† (18) | OUT:K59(1) | OUT:KUT(1) | OUT:KUT(1) | OUT:K6(3) | OUT:K38(1) |
Notes: *No. of isolates per serotype; †UT, untypeable; - indicates that this serotype was not detected in this year.
Figure 1Distribution of the main Vibrio parahaemolyticus serotypes from patients with acute diarrhoea in southeastern China from 2013 to 2017.
Haemolysin Genes of Vibro parahaemolyticus Isolates from Patients with Acute Diarrhoea in Southeastern China from 2013 to 2017
| Year | Total (n=1220) | Haemolysin Genes (%) | |||
|---|---|---|---|---|---|
| tdh+trh− (n= 1150) | tdh+trh+ (n= 13) | tdh−trh+ (n=6) | tdh−trh− (n=51) | ||
| 2013 | 204 | 194(95.1) | 1(0.5) | 2(1.0) | 7(3.4) |
| 2014 | 205 | 192(93.7) | 1(0.5) | 2(1.0) | 10(4.9) |
| 2015 | 142 | 136(95.8) | 3(2.1) | 1(0.7) | 2(1.4) |
| 2016 | 266 | 250(94.0) | 3(1.1) | 0(0.0) | 13(4.9) |
| 2017 | 403 | 378(93.8) | 5(1.2) | 1(0.2) | 19(4.7) |
Notes: + positive, presence of the gene; − negative, absence of the gene.
Distribution of Virulence Genes and Pandemic Markers in Vibrio parahaemolyticus Isolates from Patients with Acute Diarrhoea in Southeastern China from 2013 to 2017
| Haemolysin Genes | Pandemic Markers | 2013 (n=204) | 2014 (n=205) | 2015 (n=142) | 2016 (n=266) | 2017 (n=403) | |||
|---|---|---|---|---|---|---|---|---|---|
| tlh | tdh | trh | toxRS/new | orf8 | |||||
| 68(33.3) | 93(45.4) | 85(59.9) | 160(60.2) | 198(49.1) | |||||
| + | + | – | + | + | 60(29.4) | 70(34.1) | 76(53.5) | 131(49.2) | 182(45.2) |
| + | + | – | + | – | 8(3.9) | 23(11.2) | 9(6.3) | 29(10.9) | 16(4.0) |
| 136(66.7) | 112(54.6) | 57(40.1) | 106(39.8) | 205(50.9) | |||||
| + | + | - | - | - | 124(60.8) | 82(40.0) | 41(28.9) | 85(32.0) | 177(43.9) |
| + | + | - | - | + | 2(1.0) | 17(8.3) | 10(7.0) | 5(1.9) | 3(0.7) |
| + | + | + | + | + | 1(0.5) | 0(0.0) | 0(0.0) | 1(0.4) | 1(0.2) |
| + | + | + | + | - | 0(0.0) | 0(0.0) | 0(0.0) | 1(0.4) | 0(0.0) |
| + | + | + | - | - | 0(0.0) | 1(0.5) | 3(2.1) | 1(0.4) | 4(1.0) |
| + | - | - | + | - | 0(0.0) | 0(0.0) | 0(0.0) | 4(1.5) | 2(0.5) |
| + | - | - | - | - | 7(3.4) | 10(4.9) | 1(0.7) | 9(3.4) | 17(4.2) |
| + | - | - | - | + | 0(0.0) | 0(0.0) | 1(0.7) | 0(0.0) | 0(0.0) |
| + | - | + | - | - | 2(1.0) | 2(1.0) | 1(0.7) | 0(0.0) | 1(0.2) |
Figure 2Distribution of different serotypes of Vibrio parahaemolyticus isolates in pandemic and non-pandemic strains. The number on the left side of the “/” in the parenthesis on the right side of the figure is the number of pandemic strains, and the number on the right side is the number of non-pandemic strains.
Distribution of T3SS Genes Among Vibrio parahaemolyticus Strains Isolated from Patients with Acute Diarrhoea in Southeastern China During 2013–2017
| Genes | Total (n=1220) | 2013 (n=204) | 2014 (n=205) | 2015 (n=142) | 2016 (n=266) | 2017 (n=403) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VP1670[ | 1144 | 13 | 6 | 51 | 192 | 1 | 2 | 7 | 191 | 1 | 2 | 10 | 136 | 3 | 1 | 2 | 248 | 3 | 0 | 13 | 377 | 5 | 1 | 19 |
| VP1686[ | 1102 | 12 | 6 | 44 | 183 | 1 | 2 | 6 | 171 | 1 | 2 | 9 | 136 | 3 | 1 | 2 | 239 | 2 | 0 | 9 | 373 | 5 | 1 | 18 |
| VP1689[ | 1129 | 13 | 6 | 48 | 189 | 1 | 2 | 6 | 179 | 1 | 2 | 10 | 136 | 3 | 1 | 2 | 248 | 3 | 0 | 12 | 377 | 5 | 1 | 18 |
| VP1694[ | 1114 | 12 | 5 | 36 | 183 | 1 | 2 | 5 | 182 | 1 | 2 | 7 | 133 | 3 | 0 | 2 | 245 | 2 | 0 | 7 | 371 | 5 | 1 | 15 |
| | 1078 | 12 | 5 | 33 | 173 | 1 | 2 | 5 | 167 | 1 | 2 | 7 | 133 | 3 | 0 | 2 | 236 | 2 | 0 | 4 | 369 | 5 | 1 | 15 |
| VP1362[ | 1120 | 4 | 2 | 0 | 190 | 1 | 1 | 0 | 182 | 0 | 0 | 0 | 125 | 0 | 0 | 0 | 247 | 2 | 0 | 0 | 376 | 1 | 1 | 0 |
| VP1339[ | 1137 | 4 | 2 | 0 | 192 | 1 | 1 | 0 | 192 | 0 | 0 | 0 | 135 | 0 | 0 | 0 | 249 | 2 | 0 | 0 | 369 | 1 | 1 | 0 |
| VP1335[ | 1143 | 4 | 2 | 0 | 192 | 1 | 1 | 0 | 191 | 0 | 0 | 0 | 136 | 0 | 0 | 0 | 249 | 2 | 0 | 0 | 375 | 1 | 1 | 0 |
| VP1327[ | 1132 | 4 | 2 | 0 | 192 | 1 | 1 | 0 | 183 | 0 | 0 | 0 | 136 | 0 | 0 | 0 | 248 | 2 | 0 | 0 | 373 | 1 | 1 | 0 |
| | 1108 | 4 | 2 | 0 | 189 | 1 | 1 | 0 | 182 | 0 | 0 | 0 | 125 | 0 | 0 | 0 | 246 | 2 | 0 | 0 | 366 | 1 | 1 | 0 |
| | 0 | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 0 | 13 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 1 | 2 |
| | 0 | 11 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 1 |
| | 0 | 13 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 1 | 2 |
| | 0 | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
Antimicrobial Susceptibility Testing of 1220 Vibrio Parahaemolyticus Strains Isolated from Patients with Acute Diarrhoea During 2013–2017
| Antimicrobial Agent | Total (n=1220) | 2013 (n=204) | 2014 (n=205) | 2015 (n=142) | 2016 (n=266) | 2017 (n=403) | P* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | ||
| Ampicillin (AMP) | 1079(88.5) | 31(2.5) | 177(86.8) | 5(2.5) | 190(92.7) | 5(2.4) | 113(79.6) | 10(7.0) | 235(88.3) | 7(2.6) | 364(90.3) | 4(1.0) | 0.002 |
| Piperacillin/tazobactam (TZP) | 5(0.4) | 1212(99.4) | 0(0.0) | 204(100.0) | 0(0.0) | 205(100.0) | 0(0.0) | 142(100.0) | 0(0.0) | 266(100.0) | 5(1.2) | 395(98.0) | 0.096 |
| Piperacillin (PRL) | 26(2.1) | 1144(93.8) | 4(2.0) | 188(92.2) | 0(0.0) | 194(94.6) | 3(2.1) | 127(89.4) | 2(0.8) | 259(97.4) | 17(4.2) | 376(93.3) | 0.002 |
| Cefazolin (KZ) | 88(7.2) | 639(52.4) | 5(2.5) | 147(72.1) | 12(5.9) | 77(37.6) | 25(17.6) | 26(18.3) | 15(5.6) | 116(43.6) | 31(7.7) | 273(67.7) | <0.001 |
| Cefuroxime (CXM) | 42(3.4) | 542(44.5) | 1(0.5) | 145(71.1) | 12(5.9) | 66(32.2) | 8(5.6) | 41(28.9) | 4(1.5) | 125(47.0) | 17(4.2) | 165(40.9) | 0.002 |
| Ceftazidime (CAZ) | 12(1.0) | 1202(98.5) | 0(0.0) | 203(99.5) | 0(0.0) | 202(98.5) | 2(1.4) | 139(97.9) | 1(0.4) | 265(99.6) | 9(2.2) | 393(97.5) | 0.018 |
| Cefotaxime (CTX) | 18(1.5) | 1145(93.8) | 4(2.0) | 195(95.6) | 1(0.5) | 183(89.3) | 3(2.1) | 131(92.3) | 1(0.4) | 259(97.4) | 9(2.2) | 377(93.5) | 0.164 |
| Cefepime (FEP) | 11(0.9) | 857(70.2) | 0(0.0) | 158(77.5) | 0(0.0) | 116(56.6) | 0(0.0) | 78(54.9) | 1(0.4) | 187(70.3) | 10(2.5) | 318(78.9) | 0.004 |
| Cefoxitin (FOX) | 22(1.8) | 1119(91.7) | 4(2.0) | 198(97.1) | 1(0.5) | 178(86.8) | 2(1.4) | 114(80.3) | 1(0.4) | 258(97.0) | 14(3.5) | 371(92.1) | 0.021 |
| Imipenem (IPM) | 0(0.0) | 1220(100.0) | 0(0.0) | 204(100.0) | 0(0.0) | 205(100.0) | 0(0.0) | 142(100.0) | 0(0.0) | 266(100.0) | 0(0.0) | 403(100.0) | – |
| Meropenem (MEM) | 0(0.0) | 1220(100.0) | 0(0.0) | 204(100.0) | 0(0.0) | 205(100.0) | 0(0.0) | 142(100.0) | 0(0.0) | 266(100.0) | 0(0.0) | 403(100.0) | – |
| Amikacin (AK) | 9(0.7) | 966(79.2) | 1(0.5) | 176(86.3) | 1(0.5) | 150(73.2) | 1(0.7) | 93(65.5) | 1(0.4) | 201(75.6) | 5(1.2) | 346(85.9) | 0.815 |
| Gentamycin (CN) | 8(0.7) | 1188(97.3) | 0(0.0) | 203(99.5) | 0(0.0) | 204(99.5) | 0(0.0) | 139(97.9) | 1(0.4) | 258(97.0) | 7(1.7) | 384(95.3) | 0.054 |
| Ciprofloxacin (CIP) | 15(1.2) | 1173(96.2) | 0(0.0) | 203(99.5) | 0(0.0) | 199(97.1) | 3(2.1) | 132(93.0) | 2(0.8) | 262(98.5) | 10(2.5) | 377(93.5) | 0.013 |
| Levofloxacin (LEV) | 11(0.9) | 1207(98.9) | 0(0.0) | 204(100.0) | 0(0.0) | 205(100.0) | 2(1.4) | 140(98.6) | 1(0.4) | 265(99.6) | 8(2.0) | 393(97.5) | 0.035 |
| Trimethoprim/ sulfamethoxazole (SXT) | 35(2.9) | 1179(96.6) | 2(1.0) | 202(99.0) | 2(1.0) | 203(99.0) | 6(4.2) | 136(95.8) | 3(1.1) | 262(98.5) | 22(5.5) | 376(93.3) | 0.001 |
| Tetracycline (TE) | 37(3.0) | 1177(96.5) | 4(2.0) | 200(98.0) | 0(0.0) | 204(99.5) | 5(3.5) | 135(95.1) | 5(1.9) | 261(98.1) | 23(5.7) | 377(93.5) | <0.001 |
| Chloramphenicol (C) | 14(1.1) | 1195(98.0) | 0(0.0) | 203(99.5) | 0(0.0) | 205(100.0) | 3(2.1) | 135(95.1) | 0(0.0) | 265(99.6) | 11(2.7) | 387(96.0) | 0.001 |
Note: P*, difference in resistance rates.